Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks
A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.
Tag Archives: Jakafi
-
-
Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study
A new study links Xeljanz and similar drugs to an increased risk of skin cancer.
-
Opzelura Eczema Cream Investigation Announced Over Texture Problems
The eczema cream Opzelura, made from the same active ingredient as Jakafi, is being investigated for texture issues as the entire class of drugs faces scrutiny over heart and cancer…
-
Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs
Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.
-
FDA Worried Jakafi May Have Cancer, Heart Risks Similar to Xeljanz
The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.
-
Jakafi Risks Require Monitoring of Dose During First Three Months: Study
Doctors should closely monitor Jakafi patients for the first three months for signs of anemia, according to a new study.
-
Jakafi Side Effects May Be Linked to PML Brain Disease: Report
The bone marrow disease drug Jakafi may be linked to a rare and often deadly brain disease known as PML, according to a U.K. case study.
